Poly (ADP-ribose) polymerase (PARP) inhibitors are targeted therapies designed to exploit the DNA repair deficiency caused by BRCA mutations. In normal cells, PARP helps repair damaged DNA. In cancer cells with BRCA mutations, the DNA repair mechanism is already compromised. PARP inhibitors, such as olaparib, niraparib, and rucaparib, block an additional DNA repair pathway, leading to increased cell death in cancer cells. These drugs are particularly effective in patients with BRCA-mutated ovarian cancer. A PARP inhibitor (poly adenosine diphosphate-ribose polymerase inhibitor), Olaparib is the active element in Bracanat 100mg Tablet, an anticancer medication. It is used to treat prostate, pancreatic, breast, and ovarian cancer.
